Skip to main content

Table 1 Efficacy of ChAdOx1-GnGc and HAdV5-GnGc vaccines against RVF virus challenge

From: Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice

Vaccination regimen

Number sick/Total challenged

Viraemia post-challenge

(TCID50/ml)

ChAdOx1-GnGc

0/6

0

ChAdOx1-GnGc + 25μl AddaVax™

0/6

0

ChAdOx1-GnGc + 25μg Matrix-M™

0/6

0

HAdV5-GnGc

0/6

0

HAdV5-GnGc + 25μl AddaVax™

0/6

0

HAdV5-GnGc + 25μg Matrix-M™

0/6

0

Unvaccinated controls

6/6

21380

  1. For each vaccination regimen the number of mice developing clinical signs of RVF following challenge with RVF virus is shown. Viraemia, assessed by RVF virus isolation three days post-challenge, is presented as median TCID50/ml for each regimen.
Back to article page

Virology Journal

ISSN: 1743-422X